Vanguard National Trust
CRSP icon

Vanguard National Trust’s CRISPR Therapeutics CRSP Stock Holding History

Vanguard National Trust’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-20
Closed -$951 – 796
2026
Q1 		$951 Buy
+20
New +$1.05K ﹤0.01% 713

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard National Trust's CRSP Position: Q2 2026 in Review

Vanguard National Trust sold out of CRISPR Therapeutics (CRSP) in Q2 2026, closing a stake of 20 shares — an estimated $951 sold.

Vanguard National Trust first reported a position in CRSP in Q1 2026 and held it in 1 quarter. The position peaked at $951 in Q1 2026. 516 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Vanguard National Trust reported no remaining CRISPR Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Vanguard National Trust sold 20 CRISPR Therapeutics shares in Q2 2026, an estimated $951.
  • Vanguard National Trust first reported a position in CRISPR Therapeutics in Q1 2026 and held it in 1 quarter.
  • Vanguard National Trust's CRISPR Therapeutics position peaked at $951 in Q1 2026.
  • 516 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Vanguard National Trust's 13F filing for Q2 2026, filed 13 Aug 2026.